CellScape

CellScape

Bringing accessible, non-invasive prenatal genetic testing to every woman through pioneering whole fetal cell technology

Founded 2008 Series B Total: $21.30M Biotechnology, Health Care

CellScape is a biotech startup focused on revolutionizing prenatal genetic testing with their pioneering whole fetal cell technology. The company, formerly known as Saryna Medical Corp, is situated in the thriving biotech hub of Newark, California. Founded in 2008, CellScape's primary mission is to make comprehensive prenatal genetic testing accessible to all women without the need for invasive procedures that could pose risks to the fetus. The leadership team's successful track record in bringing innovative and cost-effective medical and molecular diagnostics to the market adds credibility to the venture. Their latest funding round was a Series B investment on May 10, 2013. Despite the absence of specific investors provided, this investment demonstrates ongoing support and interest in their groundbreaking technology. With a focus on biotechnology and healthcare, CellScape holds promise for making significant strides in improving prenatal care and genetic screening.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	Undisclosed	-		10 May 2013
Series B	$8.50M	-		08 May 2013
Venture Round	$1.10M	2	RA Capital Management, XSeed Capital	01 Jul 2012
Series B	$9.30M	2	XSeed Capital, Zygote Ventures	01 Feb 2012
Series A	$1.60M	2	XSeed Capital, Zygote Ventures	01 Dec 2010
Seed Round	$800.00K	1	XSeed Capital	06 May 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

Undisclosed

10 May 2013

Series B

$8.50M

08 May 2013

Venture Round

$1.10M

RA Capital Management, XSeed Capital

01 Jul 2012

Series B

$9.30M

XSeed Capital, Zygote Ventures

01 Feb 2012

Series A

$1.60M

XSeed Capital, Zygote Ventures

01 Dec 2010

Seed Round

$800.00K

XSeed Capital

06 May 2009

FAQ About CellScape

Bringing accessible, non-invasive prenatal genetic testing to every woman through pioneering whole fetal cell technology

CellScape was founded in 2008.

CellScape operates in Biotechnology and Health Care. Its work centres on prenatal genetic testing, whole fetal cell technology, non-invasive testing and biotech innovation.

CellScape has completed 6 funding rounds, raising a total of $21.30M. The latest funding stage is Series B.

Top alternatives and competitors to CellScape include BillionToOne, Molecular Stethoscope, Parabase Genomics, Testmate Health, GENZ Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

CellScape and BillionToOne are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About CellScape

Funding Rounds & Investors (6)

CellScape Alternatives & Competitors

FAQ About CellScape